Loading company…
Sydney-based cancer therapy company whose SIR-Spheres Y-90 resin microspheres treat unresectable liver cancer.
Sirtex Medical Limited develops and commercializes targeted cancer treatments, mainly SIR-Spheres Y-90 resin microspheres for unresectable liver cancer. Founded in 1997 in Sydney, Australia, it also offers the LAVA Liquid Embolic System and SIROS INSYTE with SurePlan technology to healthcare providers, mainly in Asia-Pacific, Europe and Latin America. In June 2018 the company was taken private in an AUD 1.87 billion buyout by CDH Investments and China Grand Pharmaceutical and Healthcare Holdings. Fiscal 2023 revenue was AUD 161,290,171.60 with EBITDA of AUD 19,996,137.70.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in